Keyphrases
Targeted Radionuclide Therapy
100%
Receptor Targets
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Soluble Urokinase Plasminogen Activator Receptor (suPAR)
100%
AE105
100%
Lutetium-177 (177Lu)
100%
Metastatic Lesions
41%
Prostate Cancer
33%
Positron Emission Tomography
25%
Prostate Cancer Model
16%
Bioluminescence Imaging
16%
Molecular Targets
8%
Kidney Tissue
8%
Cancer Invasion
8%
Free Survival
8%
Antimetastatic Effect
8%
High-level Expression
8%
In Cancer
8%
Targeted Radiotherapy
8%
Treatment Study
8%
Cell-based
8%
Specific Binding
8%
Competitive Binding
8%
Targeted Therapy
8%
All-small
8%
Binding Experiment
8%
Metastatic Cells
8%
Promising Strategies
8%
First Treatment
8%
Specific Activity
8%
In Vivo Data
8%
IC50 Value
8%
High Purity
8%
HE Staining
8%
Treatment Dose
8%
PC-3M
8%
Flow Cytometry
8%
Mouse Model
8%
Induced Toxicity
8%
Radionuclides
8%
Flow-ELISA
8%
Tissue Dose
8%
Radiolabeled Ligand
8%
Combined Control
8%
Binding Studies
8%
Non-specific Binding
8%
Expression Level
8%
Theranostics
8%
Medicine and Dentistry
Targeted Radionuclide Therapy
100%
Urokinase Receptor
100%
Lutetium 177
100%
Tetraxetan
100%
Prostate Cancer
100%
positron emission tomographic scan
25%
Bioluminescence
16%
Cancer Model
16%
Radiation Therapy
8%
Binding Competition
8%
Kidney Tissue
8%
Flow Cytometry
8%
Copper 64
8%
IC50
8%
Tumor Invasion
8%
Enzyme Linked Immunosorbent Assay
8%
Metastasis Free Survival
8%